Intermediate dose etoposide plus G-CSF 16 μg/kg is more effective than cyclophosphamide 4 g/m2 plus G-CSF 10 μg/kg in PBSC mobilization of lymphoma patients

Leukemia and Lymphoma

Volumn 48, Issue 10, 2007, Pages 1950-1960

  Milone, Giuseppe ^a   Leotta, Salvatore ^a   Battiato, Katia ^a   Murgano, Pamela ^a   Mercurio, Salvatore ^a   Strano, Aurora ^a   Poidomani, Massimo ^a   Coppoletta, Stefania ^a   Mauro, Elisa ^a   Avola, Giuseppe ^a   Pinto, Valeria ^a   Camuglia, Maria Grazia ^a   Giustolisi, Rosario ^a  

^a Divisione di Ematologia Pediatrica   (Italy)

Author keywords

Etoposide; Lymphoma; PBSC mobilization

Indexed keywords

CARMUSTINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CD34 SELECTION; COLONY FORMING UNIT GM; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HODGKIN DISEASE; HUMAN; INFECTION; LEUKAPHERESIS; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL MOBILIZATION; TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKAPHERESIS; LYMPHOMA; MALE; MIDDLE AGED; OUTPATIENTS; STEM CELL TRANSPLANTATION; STEM CELLS; TREATMENT OUTCOME;

EID: 35148882603     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701573240     Document Type: Article

References (43)

1. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van Der Lelie, H. and Bron, D. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 333, pp. 1540-1545.
2. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M. and Haenel, M. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet, 359, pp. 2065-2071.
3. Schouten, H. C., Qian, W., Kualoy, S., Porcellini, A., Hagberg, H. and Johnssen, H. E. (2003) High dose therapy improves progression free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized CUP trial. J Clin Oncol, 21, pp. 3918-3927.
4. Schmitz, N., Linch, D. C., Dreger, P., Goldstone, A. H., Boogaerts, M. A. and Ferrant, A. (1996) Randomised trial of filgrastim - mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet, 347, pp. 353-357.
5. Russell, N. H., McQuaker, G., Stainer, C., Byrne, J. L. and Haynes, A. P. (1998) Stem cell mobilisation in lymphoproliferative disease. Bone Marrow Transplant, 22, pp. 935-940.
6. Jantunen, E., Putkonen, M., Nousiainen, T., Pelliniemi, T-T, Mahalamaki, E. and Remes, K. (2003) Low dose or intermediate dose cyclophosphamide plus granulocyte-colony stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant, 31, pp. 347-351.
7. Fitoussi, O., Perrau, V., Boiron, J. M., Bouzigon, E., Cony-Makhoul, P. and Pigneux, A. (2001) A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant, 27, pp. 837-842.
8. Lefrere, F., Zohar, S., Ghez, D., Delarue, R., Audat, F. and Suarez, F. (2006) The VAD chemotherapy regimen plus a G-CSF dose of 10 mg/kg is as effective and less toxic than high-dose cyclophosphamide plus G-CSF dose of 5 g/kg for progenitor cell mobilization: Results from a monocentric study in 82 patients. Bone Marrow Transplant, 37, pp. 725-729.
9. Lee, J. L., Kim, S., Kim, S. W., Kim, E. K., Kim, S. B. and Kang, Y. K. (2005) ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: Comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant, 35, pp. 449-454.
10. Pavone, V., Gaudio, F., Guarini, A., Perrone, T., Zonno, A. and Curci, P. (2002) Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant, 29, pp. 285-290.
11. Gazitt, Y., Callander, N., Freytes, C. O., Shaughness, P., Liu, Q. and Tsai, T. W. (2000) Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequencial GM-CSF/ G-CSF in non-Hodgkin's lymphoma patients: A randomized study. J Hematother Stem Cell Res, 9, pp. 737-748.
12. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant, 17, pp. 691-697.
13. Copelan, E. A., Ceselski, S. K., Ezzone, S. A., Lasky, L. C., Penza, S. L. and Bechtel, T. P. (1997) Mobilization of peripheral blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol, 15, pp. 759-765.
14. Kanfer, E. J., Guigan, D Mc, Samson, D., Abboudi, Z., Abrahamson, G. and Apperley, J. F. (1998) High dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: Efficacy and toxicity at three dose levels. Br J Cancer, 78, pp. 928-932.
15. Junghanss, C., Leithauser, M., Wilhelm, S., Kleine, H. D., Knopp, A. and Decker, S. (2001) High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize. Ann Hematol, 80, pp. 96-102.
16. Raiser, M., Josting, A., Draube, A., Mapara, M. Y., Scheld, C. and Chemnitz, J. (1999) Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed mobilization. Bone Marrow Transplant, 23, pp. 1223-1228.
17. Bolwell, B. J., Kalaycio, M., Sobecks, R., Andresen, S., Kuczkowski, E. and Bernhard, L. (2002) A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant, 30, pp. 587-591.
18. Lagneaux, L., Marie, J. P., Delforge, A., Socquet, M., Thevenin, D. and Zittoun, R. (1989) Comparison of in vitro inhibition of (VP-16) on leukemic and normal myeloid, erithroid clonogenic cells. Exp Hematol, 17, pp. 843-846.
19. Milone, G., Leotta, S., Indelicato, F., Mercurio, S., Moschetti, G. and Raimondo, F Di (2003) G-CSF alone versus cyclophopsphamide plus G-CSF in PBPC mobilization of patients with lymphoma: Results depend on degree of previous pre-treatment. Bone Marrow Transplant, 31, pp. 747-754.
20. Watts, M. J., Sullivan, A. M., Jamieson, E., Pearce, R., Fielding, A. and Devereux, S. (1997) Progenitor-cell mobilization after low dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol, 15, pp. 535-546.
21. Chopra, M. W., McMillan, A., Pearce, R., Linch, D. C. and Goldstone, A. H. (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's Lymphoma. J Clin Oncol, 13, pp. 588-595.
22. Donnelly, J. P., Muus, P., Schattenberg, A., De Witte, T., Horrevorts, A. and DePauw, B. E. (1992) A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant, 9, pp. 409-413.
23. Quaker, I G Mc, Haynes, A. P., Stainer, C. and Russel, N. H. (1999) Mobilization of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Bone Marrow Transplant, 24, pp. 715-722.
24. 2 and G-CSF for pre-treated lymphoma patients: A matched pairs analysis of 78 patients. Br J Cancer, 8, pp. 278-282.
25. Goldberg, M. A., Antin, J. H., Guinan, E. C. and Rappeport, J. M. (1986) Cyclophosphamide cardiotoxicity: Analysis of dosing as a risk factor. Blood, 5, pp. 1114-1118.
26. Lieberg, C. F., Rausing, A. and Langeland, P. (1970) Cyclophosphamide hemorragic cystitis. Scand J Urol Nephrol, 4, pp. 183-190.
27. Rosenfeld, C. S., Shadduck, R. K., Zeigler, Z. R., Andrews, F. and Nemunaitis, J. (1995) Cyclophosphamide-mobilized peripheral blood stem cells in patients with lymphoid malignancies. Bone Marrow Transplant, 15, pp. 433-438.
28. Avery, R. K., Pohlman, B. L., Mossad, S. B., Goormastic, M., Longworth, D. L. and Kalaycio, M. E. (2002) The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose Etoposide (VP-16) for stem cell mobilization. Bone Marrow Transplant, 30, pp. 311-314.
29. Molle, P., Pereira, D., Nagy, T., Song, K., Saragosa, R. and Keating, A. (2002) Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cell for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplantation, 30, pp. 273-278.
30. Boeve, S., Strupeck, J., Creech, S. and Stiff, P. J. (2004) Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: Risk factors, cytokine use and cost. Bone Marrow Transplant, 33, pp. 997-1003.
31. Jindra, P., Koza, V., Lysak, D., Vozobulova, V. and Steinerova, K. (2005) Inefficiency of high-dose G-CSF alone as second mobilization regimen in fludarabin-cyclophosphamide-treated CLL patients who failed to mobilize after chemotherapy and G-CSF. Bone Marrow Transplant, 35, pp. 729-730.
32. Demirer, T., Ayli, M., Ozcan, M., Gunel, N., Haznedar, R. and Dagli, M. (2002) Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): A randomized evaluation of different doses of rhG-CSF. Br J Haematol, 116, pp. 464-474.
33. Andre, M., Baudoux, E., Bron, D., D'Hondt, V., Fassotte, M-F and D'Hondt, L. (2003) Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patient with nonmyeloid malignancies. Transfusion, 43, pp. 50-57.
34. Damon, L., Rugo, H., Tolaney, S., Navarro, M., Martin, T. and Ries, C. (2006) Cytoreduction of lymphoid malignancies and mobilizations of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant, 12, pp. 316-324.
35. Seyfarth, B., Josting, A., Dreyling, M. and Schmitz, N. (2006) Relapse in common lymphoma subtypes: Salvage treatment options in follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. Br J Haematol, 133, pp. 3-18.
36. Pedersen-Bjergaard, J. and Philip, P. (1991) Balanced translocation involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood, 78, pp. 1147-1148.
37. Krishnan, A., Bhatia, S., Slovak, M. L., Arber, D. A., Niland, J. C. and Nademanee, A. (2000) Predictors of therapy-related leukaemia and myelodyslasia following autologous transplantation for lymphoma: An assessment of risk factors. Blood, 95, pp. 1588-1593.
38. Copelan, E., Hoshaw-Woodard, S., Elder, P., Penza, S., Farag, S. and Marcucci, G. (2004) Therapy related myelodisplasia and leukaemia occur infrequently following VP-16 priming and autotransplantation without total body irradiation. Bone Marrow Transplant, 34, pp. 85-87.
39. Metayer, C., Curtis, R. E., Vose, J., Sobocinski, K., Horowitz, M. M. and Bhatia, S. (2003) Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: A multicenter case - control study. Blood, 101, pp. 2015-2023.
40. Kollmannsberger, C., Beyer, J., Droz, J. P., Harstrick, A., Hartmann, J. T. and Biron, P. (1998) Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol, 16, pp. 3386-3391.
41. Deley, M C Le, Blanc, T Le, Shamsaldin, A., Raquin, M. A., Lacour, B. and Sommelet, D. (2003) Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case control study by the société francaise d'oncologie pediatrique. J Clin Oncol, 21, pp. 1074-1081.
42. Pedersen-Bjergaard, J., Andersen, M. K. and Christiansen, D. H. (2000) Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood, 95, pp. 3273-3279.
43. Bhatia, R., Van Heijzen, K., Palmer, A., Komiya, A., Slovak, M. L. and Chang, K. L. (2005) Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol, 23, p. 6699.